Palatin Technologies, Inc., a biopharmaceutical company, develops targeted, receptor-specific peptide therapeutics for the treatment of various diseases in the United States. The company's principal product is Bremelanotide, an as needed subcutaneous injectable peptide melanocortin receptor agonist, which is in the Phase III clinical studies for the treatment of premenopausal women with hypoactive sexual desire disorder (HSDD). Its drug development programs also include melanocortin peptide system program, including PL-8177 is a selective melanocortin receptor 1 agonist peptide for inflammatory bowel diseases; and PL-8331, is a preclinical development candidate for treating ocular inflammation. In addition, the company develops natriuretic peptide system programs, including PL3994, a natriuretic peptide receptor-A agonist for treatment of cardiovascular indications; and PL-5028, s dual natriuretic peptide receptor A and C agonist that is in preclinical development for cardiovascular diseases, such as reducing cardiac hypertrophy and fibrosis. Palatin Technologies, Inc. was founded in 1986 and is based in Cranbury, New Jersey.
Industry, Sector and Symbol
Stock Exchange NYSEAMERICAN
Industry Diagnostics & Research
Sub-IndustryN/A
SectorMedical
SymbolNYSEAMERICAN:PTN
CUSIPN/A
Phone+1-609-4952200
Debt
Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A
Profitability
EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net Margins28.55%
Return on Equity155.80%
Return on Assets27.77%
Miscellaneous
EmployeesN/A
Outstanding Shares198,680,000
Market Cap$184.13
Palatin Technologies (NYSEAMERICAN:PTN) Frequently Asked Questions
What is Palatin Technologies' stock symbol?
Palatin Technologies trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "PTN."
How were Palatin Technologies' earnings last quarter?
Palatin Technologies, Inc. (NYSEAMERICAN:PTN) posted its quarterly earnings results on Tuesday, May, 15th. The biopharmaceutical company reported $0.00 earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of ($0.04) by $0.04. The biopharmaceutical company had revenue of $8.96 million for the quarter. Palatin Technologies had a return on equity of 155.80% and a net margin of 28.55%. View Palatin Technologies' Earnings History.
What price target have analysts set for PTN?
4 brokers have issued 12 month price objectives for Palatin Technologies' shares. Their predictions range from $2.00 to $6.00. On average, they expect Palatin Technologies' share price to reach $4.00 in the next year. This suggests a possible upside of 296.0% from the stock's current price. View Analyst Ratings for Palatin Technologies.
What is the consensus analysts' recommendation for Palatin Technologies?
4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Palatin Technologies in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
Are investors shorting Palatin Technologies?
Palatin Technologies saw a increase in short interest during the month of June. As of June 29th, there was short interest totalling 23,472,013 shares, an increase of 79.7% from the June 15th total of 13,059,843 shares. Based on an average trading volume of 4,142,131 shares, the days-to-cover ratio is presently 5.7 days. Approximately 12.5% of the shares of the company are short sold. View Palatin Technologies' Current Options Chain.
Who are some of Palatin Technologies' key competitors?
Some companies that are related to Palatin Technologies include Senseonics (SENS), MaxCyte (MXCT), EPIGENOMICS AG/S (EPGNY), Oncimmune (ONC), Profound Medical (PRN), Lexagene (LXG), Sernova (SVA), Co-Diagnostics (CODX), SQI Diagnostics (SQD), Parallax Health Sciences (PRLX), Cambridge Cognition (COG), LED Medical Diagnostics (LMD), 3D Signatures (DXD), GeneNews (GEN) and Oxford Advanced Surfaces Gro (CRON).
Who are Palatin Technologies' key executives?
Palatin Technologies' management team includes the folowing people:
- Dr. John K. A. Prendergast, Co-Founder & Non-Exec. Chairman (Age 64)
- Dr. Carl Spana, Co-Founder, Pres, CEO & Director (Age 56)
- Mr. Stephen T. Wills, CFO, COO, Exec. VP, Treasurer & Sec. (Age 61)
- Burns McClellan, VP of Investor Relations
- Dr. Johna Lucas M.A., M.D., F.A.C.O.G., Chief Medical Officer
Has Palatin Technologies been receiving favorable news coverage?
Media headlines about PTN stock have trended somewhat positive this week, according to Accern. The research group ranks the sentiment of press coverage by analyzing more than twenty million news and blog sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Palatin Technologies earned a daily sentiment score of 0.12 on Accern's scale. They also gave news headlines about the biopharmaceutical company an impact score of 47.50 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company's share price in the near term.
How do I buy shares of Palatin Technologies?
Shares of PTN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Palatin Technologies' stock price today?
One share of PTN stock can currently be purchased for approximately $1.01.
How big of a company is Palatin Technologies?
Palatin Technologies has a market capitalization of $184.13 million.
How can I contact Palatin Technologies?
Palatin Technologies' mailing address is 4B Cedarbrook Dr, CRANBURY, NJ 08512-3641, United States. The biopharmaceutical company can be reached via phone at +1-609-4952200.
MarketBeat Community Rating for Palatin Technologies (NYSEAMERICAN PTN)
MarketBeat's community ratings are surveys of what our community members think about Palatin Technologies and other stocks. Vote "Outperform" if you believe PTN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PTN will underperform the S&P 500 over the long term. You may vote once every thirty days.
